xanomeline has been researched along with Cognition Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou-Gharbia, M; Boast, CA; Husbands, GM; Moyer, JA; Sabb, AL; Stein, RP; Tasse, RP; Tokolics, J | 1 |
| Appenroth, D; Decker, M; Fang, L; Fleck, C; Jumpertz, S; Mohr, K; Tränkle, C; Zhang, Y | 1 |
| Bymaster, FP; Dubé, S; Felder, CC; Lienemann, J; Lightfoot, J; Mallinckrodt, C; McKinzie, DL; Potter, WZ; Shekhar, A | 1 |
| Pomara, N | 1 |
| Barak, S; Weiner, I | 1 |
| Bodick, NC; Bymaster, FP; Cutler, NR; Gauthier, SG; Hurley, DJ; Levey, AI; Offen, WW; Paul, SM; Potter, WZ; Rasmussen, K; Satlin, A; Shannon, HE; Tollefson, GD | 1 |
2 trial(s) available for xanomeline and Cognition Disorders
| Article | Year |
|---|---|
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Topics: Adolescent; Adult; Affect; Brief Psychiatric Rating Scale; Cognition Disorders; Demography; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Agonists; Neuropsychological Tests; Pyridines; Receptors, Cholinergic; Receptors, Muscarinic; Schizophrenia; Severity of Illness Index; Thiadiazoles | 2008 |
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Topics: Alzheimer Disease; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Muscarinic Agonists; Placebos; Pyridines; Thiadiazoles | 1997 |
4 other study(ies) available for xanomeline and Cognition Disorders
| Article | Year |
|---|---|
Discovery of a highly potent, functionally-selective muscarinic M1 agonist, WAY-132983 using rational drug design and receptor modelling.
Topics: Administration, Oral; Animals; Bridged-Ring Compounds; Carbachol; Cerebral Cortex; CHO Cells; Cognition Disorders; Computer Simulation; Cricetinae; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Humans; Macaca mulatta; Maze Learning; Models, Molecular; Muscarinic Agonists; Phosphatidylinositols; Protein Conformation; Pyrazines; Pyridines; Rats; Receptor, Muscarinic M1; Receptors, Muscarinic; Salivation; Structure-Activity Relationship; Thiadiazoles | 1999 |
Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Central Nervous System Agents; Cholinesterase Inhibitors; Cholinesterases; Cognition Disorders; Female; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Maze Learning; Muscarinic Agonists; Pyridines; Rats; Rats, Wistar; Receptor, Muscarinic M1; Spectrometry, Mass, Electrospray Ionization; Tacrine; Thiadiazoles | 2010 |
Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia.
Topics: Acetylcholine; Cognition Disorders; Dopamine; Hippocampus; Humans; Muscarinic Agonists; Neocortex; Pyridines; Receptor, Muscarinic M1; Schizophrenia; Thiadiazoles | 2009 |
The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Topics: Amphetamine; Animals; Antimanic Agents; Behavior, Animal; Cognition Disorders; Dizocilpine Maleate; Dose-Response Relationship, Drug; Kinetics; Male; Molecular Targeted Therapy; Muscarinic Agonists; Neural Inhibition; Neurotransmitter Agents; Pyridines; Rats; Rats, Wistar; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Scopolamine; Tachyphylaxis; Thiadiazoles | 2011 |